ANTICCR5 RIBOZYMES TO INHIBIT HIV1 INFECTION

Information

• Research Project
• 2646777

• ApplicationId

  2646777

• Core Project Number

  R43AI043144

• Full Project Number

  1R43AI043144-01

• Serial Number

  43144

• FOA Number

• Sub Project Id

• Project Start Date

  6/1/1998 - 26 years ago

• Project End Date

  11/30/1998 - 25 years ago

• Program Officer Name

• Budget Start Date

  6/1/1998 - 26 years ago

• Budget End Date

  11/30/1998 - 25 years ago

• Fiscal Year

  1998

• Support Year

  1

• Suffix

• Award Notice Date

  5/19/1998 - 26 years ago

Organizations

• ITHERX PHARMACEUTICALS, INC.

DESCRIPTION: This is an SBIR grant (Phase I) application to develop and test in vitro ribozymes targeted at the CCR5 co-receptor for M-tropic primary HIV-1 isolates. The applicants will test selected ribozymes initially in PM1 cells, later in primary T-cells and the progeny of stem cells, using various viral vectors and promoters. PROPOSED COMMERCIAL APPLICATION: Proposed commercial application not available.

IC Name

• Activity

  R43

• Administering IC

  AI

• Application Type

  1

• Direct Cost Amount

• Indirect Cost Amount

• Total Cost

• Sub Project Total Cost

• ARRA Funded

• CFDA Code

  856

• Ed Inst. Type

• Funding ICs

• Funding Mechanism

• Study Section

  ZRG5

• Study Section Name

• Organization Name

  ITHERX PHARMACEUTICALS, INC.

• Organization Department

• Organization DUNS

• Organization City

  SAN DIEGO

• Organization State

  CA

• Organization Country

  UNITED STATES

• Organization Zip Code

  921211508

• Organization District

  UNITED STATES